<DOC>
	<DOCNO>NCT01860807</DOCNO>
	<brief_summary>The objective study test safety potential efficacy ibudilast treat methamphetamine dependence . The study hypotheses ibudilast reduce methamphetamine use increase treatment retention placebo among patient seek treatment methamphetamine dependence . As HIV infection common complication methamphetamine dependence , half participant HIV positive study ass whether ibudilast also improve HIV relate outcome ( e.g . medication adherence , CD4 count , risk behavior ) .</brief_summary>
	<brief_title>Trial Ibudilast Methamphetamine Dependence</brief_title>
	<detailed_description>Ibudilast ( IBUD ) macrophage migration inhibitory factor ( MIF ) phosphodiesterase ( PDE ) -4 -10 inhibitor peak clinical exposure ( Rolan , Hutchinson et al . 2009 ) increase glial cell line-derived neurotrophic factor ( GDNF ) expression ( Mizuno , Kurotani et al . 2004 ) reduce microglial activation ( Suzumura , Ito et al . 1999 ; Suzumura , Ito et al . 2003 ) , include HIV-induced glial activation ( Kiebala Maggirwar 2011 ) . IBUD significantly reduce methamphetamine ( MA ) prime- stress-induced reinstatement MA seek rat ( Beardsley , Shelton et al . 2010 ) multiple effect may make effective treatment MA dependence include amelioration dopaminergic neuroinflammatory dysfunction . Multiple study implicate glial cell variety neurodegenerative disease ( Hirsch Hunot 2009 ; Sidoryk-Wegrzynowicz , Wegrzynowicz et al . 2011 ) include MA dependence HIV infection ( Nath 2010 ) . Activated glial cell secrete pro-inflammatory mediator ( Minghetti , Ajmone-Cat et al . 2005 ) may exacerbate MA-induced dopaminergic dysfunction . Glial cell also produce neurotrophic factor , include GDNF , may ameliorate dopaminergic dysfunction ( Pascual , Hidalgo-Figueroa et al . 2008 ) . Thus , IBUD may effective medication MA dependence due modulation glial cell activation result amelioration dopaminergic neurocognitive dysfunction improve treatment outcome MA dependence . IBUD may also unique effect HIV positive MA user may additionally block degradation neuronal integrity see HIV infection ( Chana , Everall et al . 2006 ; Dash , Gorantla et al . 2011 ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Ibudilast</mesh_term>
	<criteria>1 . 18 year age old ; 2. meet DSMIVTR criterion MA dependence ( SCID verify ) ; 3. MApositive urine drug screen one visit two week leadin period ; 4. seek treatment MA problem ; 5. willing able comply study procedure ; 6. provide write informed consent ; 7 . English speak 8. reside within 35 mile clinical research site ; 9. female childbearing potential , pregnant lactate willing use medically reliable method birth control trial ( e.g. , birth control pill , DepoProvera , and/or condom spermicide ) . 1. medical condition , study physician 's judgment , may interfere safe study participation ( e.g. , active TB ; unstable cardiac , renal , liver disease ; uncontrolled hypertension ; unstable diabetes ) ; 2 . CD4 count &lt; 50 cells/mm3 ( suggestive advance HIV infection ) 3 . AST , ALT , GGT &gt; 3 time upper normal limit ; 4 . A corrected QT &gt; 450 msec men &gt; 460 msec woman least two ECGs baseline period , clinical risk factor Torsades de Pointes ( e.g . ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) , require ongoing treatment concomitant medication ( ) establish risk Torsades de Pointes ( e.g . Amiodarone , Arsenic trioxide , Astemizole , Bepridil , Chloroquine , Chlorpromazine , Cisapride , Citalopram , Clarithromycin , Disopyramide , Dofetilide , Domperidone , Droperidol , Erythromycin , Flecainide , Halofantrine , Haloperidol , Ibutilide , Levomethadyl , Mesoridazine , Methadone , Moxifloxacin , Pentamidine , Pimozide , Probucol , Procainamide , Quinidine , Sotalol , Sparfloxacin , Terfenadine , Thioridazine , Vandetanib ) ; 5. current ongoing treatment psychotropic medication ( e.g. , antidepressant , antipsychotic , antiepileptic , sedative/hypnotics , narcotic analgesic ) ; 6. neurological disorder ( e.g. , organic brain disease , dementia ) medical condition would make study agent compliance difficult would compromise informed consent ; 7. major psychiatric disorder due substance abuse ( e.g. , schizophrenia , bipolar disorder ) assess SCID ; 8. attempt suicide past 3 year and/or serious suicidal intention plan past year assess CSSRS ; 9. currently prescription medication contraindicate use IBUD include alpha beta agonist , theophylline , sympathomimetics ; 10. current dependence cocaine , opiates , alcohol , benzodiazepine define DSMIVTR ; 11. alcohol dependence within past year ; 12. great one urine specimens leadin riboflavin concentration &lt; 900 ng/ml assess via UV fluorescence ; 13. history sensitivity IBUD ; 14. circumstance , opinion investigator , would compromise participant safety ; 15. current participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>methamphetamine</keyword>
	<keyword>ibudilast</keyword>
	<keyword>HIV</keyword>
</DOC>